Early career researchers are instrumental in expanding Victoria’s investigator and clinical trial workforce. With access to support, you can lead the entire process from protocol development to data collection, analysis, and importantly, interpretation and translation of results into further research questions and proposed clinical application.
Drs Alesha Thai and George Au-Yeung will share their principal investigator experiences with you, including the challenges of a first trial, lessons learnt and achievements gained.
Investigator-initiated clinical trials improve treatment standards and increase knowledge for better patient care.
The VCCC Investigator-Initiated Trial Capacity Building Program is a key step towards building your clinical trials expertise. Through the program, you can access:
Do you have an investigator-initiated trial idea, but not sure how to progress it?
VCCC Clinical Trial Lead, Professor Mark Rosenthal and VCCC Program Manager, Kate Khamly will explore the support process and opportunities, as well as defining the services provided.
Mark provides leadership to the VCCC's clinical trials portfolio, capitalising on the members’ size, scale and scope to boost innovative clinical trials capability and capacity. Working closely with Anne Woollett, Head of Clinical Trial Programs and her team, Mark provides strategic direction and advice to drive a cohesive multi-pronged approach to deliver an expanded clinical trial portfolio.
George is a clinician-researcher at Peter MacCallum Cancer Centre, and has a research interest in immunology and molecular biology of ovarian cancer. He completed his PhD in Professor David Bowtell’s laboratory, investigating novel therapeutic strategies for Cyclin E1 amplified high grade serous ovarian cancer, a subset of ovarian cancers that behave aggressively and lack treatment options. He is now a full-time medical oncologist, working across the gynae-oncology and melanoma services. He is the PI on two investigator-initiated trials, one directly based on work arising from his PhD. He was also a past member of the MOGA Executive, and a current member of the RACP Advanced Trainee Committee for Medical Oncology and steering committee member for the ANZGOG OASIS initiative.
Alesha is an early career medical oncologist with sub-speciality interest in lung cancer and head and neck cancers. After completing her medical oncology training, she pursued a two-year fellowship in head and neck cancer at Peter MacCallum Cancer Centre, during which time she was part of the team that demonstrated the remarkable activity of immunotherapy for cutaneous carcinoma of the skin. Alesha is currently undertaking Masters by research where she is exploring the immunologic basis for virally driven head and neck cancers.
Can't attend in person? Register for Webinar
